Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 6, 2009, Pages 970-981

  Shimoyama, Shouji ^a  

^a Settlement Clinic   (Japan)

Author keywords

Cisplatin; Fluorouracil; Gastric cancer; Pharamacogenetics

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYURIDINE MONOPHOSPHATE; FLUORODEOXYURIDINE TRIPHOSPHATE; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURIDINE DIPHOSPHATE; FLUOROURIDINE MONOPHOSPHATE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; EXCISION REPAIR; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PYRIMIDINEMIA; PYRIMIDINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OROTATE PHOSPHORIBOSYLTRANSFERASE; PHARMACOGENETICS; PYRIMIDINES; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 66549094282     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05856.x     Document Type: Review

References (114)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006 24 : 2137 50.
2. Nakajima T, Kinoshita T, Nashimoto A et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br. J. Surg. 2007 94 : 1468 76.
3. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007 357 : 1810 20.
4. Boku N, Yamamoto S, Shirao K et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versis combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc. ASCO 2007 25 : LBA4513.
5. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008 9 : 215 21.
6. Lenz H-J, Lee F-C, Haller DG et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007 109 : 33 40. (Pubitemid 46120192)
7. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 47 : 2203 6.
8. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet 1989 16 : 215 37.
9. Wei X, Elizondo G, Sapone A et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998 51 : 391 400. (Pubitemid 28413205)
10. Van Kuilenburg AB, Vreken P, Abeling NG et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 1999 104 : 1 9. (Pubitemid 29134634)
11. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med. 1985 313 : 245 9.
12. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 1988 81 : 47 51. (Pubitemid 18092231)
13. Hasegawa T, Kim HS, Fukushima M, Wataya Y. Sequence analysis of the 5′-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil. Nucleosides Nucleotides Nucleic Acids 2005 24 : 233 42.
14. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 1996 98 : 610 15.
15. He YF, Wei W, Zhang X et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J. Clin. Pharm. Ther. 2008 33 : 307 14.
16. Magné N, Etienne-Grimaldi MC, Cals L et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br. J. Clin. Pharmacol. 2007 64 : 237 40.
17. van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 2001 7 : 1149 53.
18. Seck K, Riemer S, Kates R et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 2005 11 : 5886 92.
19. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn. J. Cancer Res. 2001 92 : 337 42.
20. Ridge SA, Sludden J, Brown O et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 1998 46 : 151 6.
21. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002 3 : 485 92.
22. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000 10 : 217 23.
23. Gross E, Ullrich T, Seck K et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum. Mutat. 2003 22 : 498 506.
24. McLeod HL, Collie-Duguid ES, Vreken P et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998 8 : 455 9.
25. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res. 1986 6 : 781 4.
26. Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res. 1996 2 : 507 10.
27. Sohn DR, Cho MS, Chung PJ. Dihydropyrimidine dehydrogenase activity in a Korean population. Ther. Drug Monit. 1999 21 : 152 4.
28. Morsman JM, Sludden J, Ameyaw MM et al. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br. J. Clin. Pharmacol. 2000 50 : 269 72.
29. Fleming RA, Milano G, Thyss A et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992 52 : 2899 902.
30. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 1994 12 : 2248 53.
31. Di Paolo A, Danesi R, Falcone A et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann. Oncol. 2001 12 : 1301 6.
32. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 2000 278 : 175 84.
33. Takechi T, Okabe H, Fujioka A, Murakami Y, Fukushima M. Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn. J. Cancer Res. 1998 89 : 1144 53.
34. Miyamoto S, Ochiai A, Boku N et al. Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int. J. Oncol. 2001 18 : 705 13.
35. Zhou ZW, Wang GQ, Wan de S et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007 53 : 127 31.
36. Gamelin E, Boisdron-Celle M, Guérin-Meyer V et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 1999 17 : 1105 10.
37. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin. Cancer Res. 2004 10 : 2652 8.
38. 13C]uracil metabolism in normal and DPD-deficient dogs. Nucleosides Nucleotides Nucleic Acids 2006 25 : 1205 9.
39. 13C] dihydrouracil. Clin. Cancer Res. 2006 12 : 549 55.
40. Ito S, Kawamura T, Inada M et al. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. Br. J. Clin. Pharmacol. 2005 60 : 584 93.
41. Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet. Genomics 2007 17 : 973 87.
42. Hamajima N, Kouwaki M, Vreken P et al. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am. J. Hum. Genet. 1998 63 : 717 26.
43. van Kuilenburg AB, Meinsma R, Zonnenberg BA et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin. Cancer Res. 2003 9 : 4363 7.
44. Luo HR, Lü XM, Yao YG et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet. 2002 40 : 41 51.
45. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL. Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 2000 16 : 1 6.
46. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 1995 20 : 191 7.
47. Kawakami K, Omura K, Kanehira E, Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 1999 19 : 3249 52.
48. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 2001 19 : 383 6.
49. Kawakami K, Salonga D, Park JM et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 2001 7 : 4096 101.
50. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001 1 : 65 70. (Pubitemid 33757985)
51. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 2005 11 : 3778 83.
52. Villafranca E, Okruzhnov Y, Dominguez MA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 2001 19 : 1779 86.
53. Ott K, Vogelsang H, Marton N et al. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int. J. Cancer 2006 119 : 2885 94.
54. Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin. Colorectal. Cancer 2001 1 : 175 8.
55. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999 58 : 310 12.
56. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 2005 23 : 1365 9.
57. Hitre E, Budai B, Adleff V et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics 2005 15 : 723 30.
58. Tsuji T, Hidaka S, Sawai T et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 2003 9 : 3700 4.
59. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res. 1987 15 : 1259 70.
60. Mandola MV, Stoehlmacher J, Muller-Weeks S et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003 63 : 2898 904.
61. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 2003 63 : 6004 7.
62. Gusella M, Bolzonella C, Crepaldi G, Ferrazzi E, Padrini R. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J. 2006 6 : 421 4.
63. Lincz LF, Scorgie FE, Garg MB, Ackland SP. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int. J. Cancer 2007 120 : 1930 4.
64. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 2000 9 : 1381 5.
65. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF. Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J. Hum. Genet. 2006 51 : 155 60.
66. Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004 14 : 319 27.
67. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 2005 11 : 3778 83.
68. Curtin K, Ulrich CM, Samowitz WS et al. Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. Int. J. Cancer 2007 120 : 2226 32.
69. Popat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann. Oncol. 2006 17 : 1810 17.
70. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 2004 22 : 529 36.
71. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 2002 62 : 3361 4.
72. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J. Inher. Metab. Dis. 1996 19 : 589 94.
73. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995 10 : 111 13.
74. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 2000 151 : 862 77.
75. Kono S, Chen K. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci. 2005 96 : 535 42.
76. Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997 95 : 2032 6.
77. Wilcken B, Bamforth F, Li Z et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 2003 40 : 619 25.
78. van der Put NM, Gabreëls F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet. 1998 62 : 1044 51.
79. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am. J. Epidemiol. 2003 157 : 571 82.
80. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 1998 64 : 169 72.
81. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 2003 9 : 1611 15.
82. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004 14 : 785 92.
83. Etienne MC, Ilc K, Formento JL et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer 2004 90 : 526 34.
84. Kitajima M, Takita N, Hata M et al. The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. Oncol. Rep. 2006 15 : 161 5.
85. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin. Cancer Res. 2006 12 : 3928 34.
86. Suchi M, Mizuno H, Kawai Y et al. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am. J. Hum. Genet. 1997 60 : 525 39.
87. De Vita F, Orditura M, Matano E et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer 2005 92 : 1644 9.
88. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S- transferase family of enzymes. Mutat. Res. 2001 482 : 21 6.
89. Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn. J. Cancer Res. 2002 93 : 1047 56.
90. Ban N, Takahashi Y, Takayama T et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 1996 56 : 3577 82.
91. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys. 1999 366 : 89 94. (Pubitemid 29394233)
92. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998 19 : 275 80.
93. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998 8 : 27 31. (Pubitemid 28097598)
94. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 2006 12 : 3050 6.
95. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 2002 94 : 936 42.
96. Goekkurt E, Hoehn S, Wolschke C et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 2006 94 : 281 6.
97. Ruzzo A, Graziano F, Kawakami K et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol 2006 24 : 1883 91.
98. Abdel-Rahman SZ, el-Zein RA, Anwar WA, Au WW. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett. 1996 107 : 229 33.
99. London SJ, Yuan JM, Chung FL et al. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet 2000 356 : 724 9.
100. Petros WP, Hopkins PJ, Spruill S et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 2005 23 : 6117 25.
101. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 2004 91 : 344 54.
102. Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW. Human DNA repair systems: an overview. Environ. Mol. Mutagen. 1999 33 : 3 20. (Pubitemid 29069822)
103. Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000 21 : 551 5.
104. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001 61 : 8654 8.
105. Monzo M, Moreno I, Navarro A et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology 2007 72 : 364 70.
106. Spitz MR, Wu X, Wang Y et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001 61 : 1354 7.
107. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 2004 15 : 1194 203.
108. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001 22 : 593 7.
109. Caggana M, Kilgallen J, Conroy JM et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol. Biomarkers Prev. 2001 10 : 355 60.
110. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 2005 11 : 6212 17.
111. Yu JJ, Mu C, Lee KB et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 1997 382 : 13 20. (Pubitemid 28376643)
112. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 2000 16 : 555 60.
113. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004 10 : 4939 43.
114. Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 2005 11 : 1534 8.